[go: up one dir, main page]

NO20054398L - 4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose - Google Patents

4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose

Info

Publication number
NO20054398L
NO20054398L NO20054398A NO20054398A NO20054398L NO 20054398 L NO20054398 L NO 20054398L NO 20054398 A NO20054398 A NO 20054398A NO 20054398 A NO20054398 A NO 20054398A NO 20054398 L NO20054398 L NO 20054398L
Authority
NO
Norway
Prior art keywords
treatment
acid derivatives
ylmethoxy
oxazol
cyclohexyloxy
Prior art date
Application number
NO20054398A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054398D0 (no
Inventor
Heiner Glombik
Eugen Falk
Hans-Ludwig Schaefer
Stefanie Keil
Dirk Gretzke
Christian Stapper
Jochen Goerlitzer
Wolfgang Wendler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20054398D0 publication Critical patent/NO20054398D0/no
Publication of NO20054398L publication Critical patent/NO20054398L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20054398A 2003-02-27 2005-09-22 4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose NO20054398L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001586 WO2004076428A1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (2)

Publication Number Publication Date
NO20054398D0 NO20054398D0 (no) 2005-09-22
NO20054398L true NO20054398L (no) 2005-11-02

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20054408A NO20054408L (no) 2003-02-27 2005-09-22 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
NO20054396A NO20054396L (no) 2003-02-27 2005-09-22 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
NO20054398A NO20054398L (no) 2003-02-27 2005-09-22 4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO20054408A NO20054408L (no) 2003-02-27 2005-09-22 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
NO20054396A NO20054396L (no) 2003-02-27 2005-09-22 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose

Country Status (34)

Country Link
US (5) US7259177B2 (pl)
EP (3) EP1599455B1 (pl)
JP (3) JP2006519194A (pl)
KR (3) KR20050105492A (pl)
CN (3) CN100439345C (pl)
AR (3) AR043427A1 (pl)
AT (3) ATE430738T1 (pl)
AU (3) AU2004215672B2 (pl)
BR (3) BRPI0407814A (pl)
CA (3) CA2516620A1 (pl)
CL (2) CL2004000391A1 (pl)
CO (2) CO5690578A2 (pl)
DE (4) DE10308355A1 (pl)
DK (3) DK1599455T3 (pl)
EC (2) ECSP055986A (pl)
ES (3) ES2326418T3 (pl)
HR (3) HRP20050742A2 (pl)
IL (2) IL170316A (pl)
MA (3) MA27736A1 (pl)
MX (3) MXPA05008988A (pl)
NO (3) NO20054408L (pl)
OA (2) OA13035A (pl)
PA (1) PA8596801A1 (pl)
PE (3) PE20040959A1 (pl)
PL (3) PL377735A1 (pl)
PT (3) PT1599452E (pl)
RS (1) RS20050594A (pl)
RU (3) RU2005129995A (pl)
SA (1) SA04250153A (pl)
TN (2) TNSN05206A1 (pl)
TW (3) TW200510352A (pl)
UY (2) UY28210A1 (pl)
WO (3) WO2004076427A1 (pl)
ZA (2) ZA200505768B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039533B4 (de) 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039532B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
BRPI0621960A2 (pt) 2006-08-10 2011-12-27 Wood One Co Ltd composiÇço hipoglicÊmica contendo derivado da casca de acÁcia
JP5340287B2 (ja) 2007-08-16 2013-11-13 ソルヴェイ（ソシエテ アノニム） ４−フルオロ置換３−オキソ−アルカン酸のエステル類の調製方法
US8399685B2 (en) 2008-02-29 2013-03-19 Nissan Chemical Industries, Ltd. Process for producing thiophene compound and intermediate thereof
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
KR102640007B1 (ko) 2017-12-13 2024-02-27 캐논 가부시끼가이샤 프로세스 카트리지
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
CA2264243C (en) 1996-08-30 2004-10-05 Novo Nordisk A/S Glp-1 derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
CN1190434C (zh) 1996-12-31 2005-02-23 雷迪实验室有限公司 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2001510195A (ja) 1997-07-16 2001-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合化１，２，４−チアジアジン誘導体、その調製及び使用
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
WO2000012491A1 (fr) * 1998-08-27 2000-03-09 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique et medicaments dont ils sont le principe actif
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
MXPA01010880A (es) 1999-04-28 2002-05-06 Aventis Pharma Gmbh Derivados de acido diarilico como ligandos de receptor ppar.
EE200100558A (et) * 1999-04-28 2002-12-16 Aventis Pharma Deutschland Gmbh Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
CA2376919C (en) 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
WO2001004146A2 (en) 1999-07-09 2001-01-18 Cohesion Technologies, Inc. Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
PT1204654E (pt) 1999-07-29 2003-11-28 Lilly Co Eli Benzofurilpiperazinas agonistas do receptor 5-ht2c da serotonina
CA2383781A1 (en) 1999-09-01 2001-03-08 Aventis Pharma Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PL357118A1 (pl) 1999-12-03 2004-07-12 Astrazeneca Ab Postać krystaliczna kwasu (S)-2-etoksy-3-[4-(2-{4-metanosulfonyloksyfenylo} etoksy) fenylo] propanowego
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
EP2266665B1 (en) 2000-03-31 2016-05-11 Royalty Pharma Collection Trust Method for the improvement of islet signaling in diabetes mellitus and for its prevention
KR20030007548A (ko) 2000-04-25 2003-01-23 교린 세이야꾸 가부시키 가이샤 티아졸리딘디온 유도체의 신규한 안정한 결정 및 이의제조방법
PT1277736E (pt) 2000-04-28 2007-10-12 Asahi Kasei Pharma Corp Novos compostos bicíclicos
BR0110638A (pt) 2000-05-11 2003-03-25 Bristol Myers Squibb Co Análogos de tetraidroisoquinolina úteis como secretagogos de hormÈnio do crescimento
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
SK17252002A3 (sk) 2000-06-09 2003-05-02 Aventis Pharma Deutschland Gmbh Deriváty acylfenylmočoviny, spôsoby ich výroby a použitie ako liečivo
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
EA200300286A1 (ru) * 2000-08-23 2003-08-28 Эли Лилли Энд Компани Агонисты активируемых пероксисомальным пролифератором рецепторов
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
CA2431983C (en) 2000-12-21 2010-06-08 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenylazetidinones, processes for their preparation, medicaments comprising these compounds and their use for treating impaired lipid metabolism
EP1726586A1 (en) * 2000-12-25 2006-11-29 Ono Pharmaceutical Co., Ltd. Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
JP2004529097A (ja) 2001-02-15 2004-09-24 ファイザー・プロダクツ・インク Ｐｐａｒアゴニスト
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
MXPA03010903A (es) * 2001-06-07 2004-02-17 Lilly Co Eli Moduladores de receptores activados por el proliferador de peroxisomas.
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
JP4436129B2 (ja) 2001-08-31 2010-03-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用
WO2003066581A1 (en) 2002-02-05 2003-08-14 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
EP1656368A4 (en) 2002-07-09 2009-08-26 Bristol Myers Squibb Co SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS AND ANTIABESITY AND THEIR MANUFACTURING PROCESS
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
WO2004076427A1 (de) 2004-09-10
PL377735A1 (pl) 2006-02-20
US7365084B2 (en) 2008-04-29
US20050101637A1 (en) 2005-05-12
PE20040959A1 (es) 2005-01-17
CO5690580A2 (es) 2006-10-31
ATE430738T1 (de) 2009-05-15
RU2005129995A (ru) 2006-01-27
JP2006519199A (ja) 2006-08-24
PT1599453E (pt) 2009-07-14
CN1753879A (zh) 2006-03-29
RU2005129992A (ru) 2006-02-10
MA27736A1 (fr) 2006-02-01
JP2006519194A (ja) 2006-08-24
PE20050292A1 (es) 2005-05-24
MA27742A1 (fr) 2006-02-01
MXPA05008988A (es) 2005-10-18
DK1599452T3 (da) 2007-10-01
KR20050106461A (ko) 2005-11-09
EP1599453B1 (de) 2009-05-06
ATE365159T1 (de) 2007-07-15
TW200500349A (en) 2005-01-01
AU2004215673B2 (en) 2009-10-01
AR043433A1 (es) 2005-07-27
PL378437A1 (pl) 2006-04-03
SA04250153A (ar) 2005-12-03
MXPA05008995A (es) 2005-10-18
TW200510352A (en) 2005-03-16
AU2004215673A1 (en) 2004-09-10
CN1756748A (zh) 2006-04-05
ECSP055986A (es) 2006-01-16
UY28209A1 (es) 2004-09-30
CA2517381A1 (en) 2004-09-10
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
AU2004215677A1 (en) 2004-09-10
MXPA05008951A (es) 2005-11-04
WO2004076428A1 (de) 2004-09-10
OA13035A (en) 2006-11-10
AU2004215677B2 (en) 2010-01-07
RU2005130002A (ru) 2006-01-27
AU2004215672B2 (en) 2010-01-07
TNSN05206A1 (en) 2007-06-11
ES2326418T3 (es) 2009-10-09
WO2004076426A1 (de) 2004-09-10
NO20054396D0 (no) 2005-09-22
CA2517386A1 (en) 2004-09-10
BRPI0407814A (pt) 2006-02-14
EP1599453A1 (de) 2005-11-30
AU2004215672A1 (en) 2004-09-10
US20040209920A1 (en) 2004-10-21
ATE435217T1 (de) 2009-07-15
PE20050293A1 (es) 2005-05-24
EP1599452B1 (de) 2007-06-20
EP1599452A1 (de) 2005-11-30
DE502004009690D1 (de) 2009-08-13
CA2516620A1 (en) 2004-09-10
US7335671B2 (en) 2008-02-26
NO20054408D0 (no) 2005-09-22
MA27737A1 (fr) 2006-02-01
BRPI0407758A (pt) 2006-02-14
CN100439347C (zh) 2008-12-03
HRP20050742A2 (en) 2006-09-30
HRP20050744A2 (en) 2006-09-30
TW200508210A (en) 2005-03-01
PT1599455E (pt) 2009-09-29
RS20050594A (en) 2007-12-31
US20050215596A1 (en) 2005-09-29
OA13034A (en) 2006-11-10
NO20054396L (no) 2005-11-11
AR043432A1 (es) 2005-07-27
EP1599455A1 (de) 2005-11-30
ZA200505768B (en) 2005-11-23
EP1599455B1 (de) 2009-07-01
CL2004000391A1 (es) 2005-01-07
CO5690578A2 (es) 2006-10-31
US7259177B2 (en) 2007-08-21
ES2329366T3 (es) 2009-11-25
CN100398526C (zh) 2008-07-02
NO20054398D0 (no) 2005-09-22
US20080015238A1 (en) 2008-01-17
KR20050106462A (ko) 2005-11-09
DK1599453T3 (da) 2009-08-24
JP2006519193A (ja) 2006-08-24
DE502004004139D1 (de) 2007-08-02
PT1599452E (pt) 2007-09-12
US7872034B2 (en) 2011-01-18
ZA200505765B (en) 2006-05-31
TNSN05204A1 (en) 2007-06-11
AR043427A1 (es) 2005-07-27
DE10308355A1 (de) 2004-12-23
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
CL2004000392A1 (es) 2005-04-22
US20080167354A1 (en) 2008-07-10
BRPI0407907A (pt) 2006-02-14
CN1753881A (zh) 2006-03-29
CN100439345C (zh) 2008-12-03
ECSP055985A (es) 2006-01-16
KR20050105492A (ko) 2005-11-04
IL170314A (en) 2010-11-30
DK1599455T3 (da) 2009-11-09
DE502004009453D1 (de) 2009-06-18
ES2287700T3 (es) 2007-12-16
UY28210A1 (es) 2004-09-30
PL378130A1 (pl) 2006-03-06

Similar Documents

Publication Publication Date Title
NO20054398L (no) 4-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksyloksy)-butansyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
NO20092293L (no) Sulfonyl-fenyl-2H-[1,2,4]oksodiazol-5-onderivater, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytiske midler
WO2007033231A3 (en) Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
WO2008033460A3 (en) Treating pain, diabetes, and lipid metabolism disorders
NO20081367L (no) Fenyl- og pyridyl-1,2,4-oksadiazolonderivater med fenylgruppe, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytika
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
NO20054382L (no) Diarylsykloalkylderivater, deres fremstilling og deres anvendelse som legemiddel
NO20081682L (no) 4-oksy-N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for deres fremstilling og deres anvendelse som farmasoytika
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
WO2007048220A3 (en) Trazodone composition for once a day adminisitiation
NO20052914L (no) Terapeutiske forbindelser
NO20064981L (no) Oksadiazolonderivater som PPAR delta agonister
NO20072542L (no) Pyrimidinderivat kondensert med ikke-aromatisk ring
NO20072389L (no) Substituerte benzokinolizinderivater
NO20081681L (no) N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
NO20085052L (no) 4-((fluorofenoksyl)fenylmetyl)piperidin metansulfonat: anvendelser, synteseprosess og farmasoytiske sammensetninger
WO2008043024A3 (en) Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
NO20081675L (no) Cykliske N-[1,3,4]-tiadiazol-2-yl-benzensulfonamlder, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
NO20054381L (no) 1,3-substituerte sykloalkylderivater med sure, som oftest heterosykliske grupper, deres fremstilling og deres anvendelse som legemiddel
NO20080860L (no) Substituert propanamidderivat og farmasoytisk preparat som inneholder dette
EA200701868A1 (ru) Производные аминобутановой кислоты, ингибирующие cpt
MXPA05008990A (es) Derivados de acido alcanoico sustituido con cicloalquilo, metodos para su produccion y su uso como medicamentos.